AidsmapThe uptake of COVID-19 vaccination follows patterns seen in the wider population, with significant disparities within and between countries, according to data presented at this week’s Conference on Retroviruses and Opportunistic infections (CROI 2022).
Presented by Evelynne Fulda from the Massachusetts General Hospital in Boston, the study was conducted within a global study called REPRIEVE (Randomised Trial to Prevent Vascular Events in HIV). With almost 8000 participants in 12 countries, REPRIEVE is a randomised, placebo-controlled trial that investigates the efficacy of providing a statin to people with HIV as a prevention strategy against major cardiovascular events. To be included in REPRIEVE, participants must be aged 40-75, be on stable antiretroviral therapy, and have no known cardiovascular disease.
Read the full story at Aidsmap.
All Aidsmap reports from CROI 2022.
Source : Aidsmap
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.